Cisplatin

Cisplatin

Clinical data
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Intravenous
ATC code	L01XA01 (WHO)
Pharmacokinetic data
Bioavailability	complete
Protein binding	> 90%
Elimination half-life	30-100 hours
Excretion	Renal
Identifiers
IUPAC name cis-diamminedichloroplatinum(II)
CAS Number	15663-27-1
PubChem CID	84691
DrugBank	APRD00359
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	Cl2H6N2Pt
Molar mass	300.05 g/mol

WikiDoc Resources for Cisplatin
Articles
Most recent articles on Cisplatin Most cited articles on Cisplatin Review articles on Cisplatin Articles on Cisplatin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cisplatin Images of Cisplatin Photos of Cisplatin Podcasts & MP3s on Cisplatin Videos on Cisplatin
Evidence Based Medicine
Cochrane Collaboration on Cisplatin Bandolier on Cisplatin TRIP on Cisplatin
Clinical Trials
Ongoing Trials on Cisplatin at Clinical Trials.gov Trial results on Cisplatin Clinical Trials on Cisplatin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cisplatin NICE Guidance on Cisplatin NHS PRODIGY Guidance FDA on Cisplatin CDC on Cisplatin
Books
Books on Cisplatin
News
Cisplatin in the news Be alerted to news on Cisplatin News trends on Cisplatin
Commentary
Blogs on Cisplatin
Definitions
Definitions of Cisplatin
Patient Resources / Community
Patient resources on Cisplatin Discussion groups on Cisplatin Patient Handouts on Cisplatin Directions to Hospitals Treating Cisplatin Risk calculators and risk factors for Cisplatin
Healthcare Provider Resources
Symptoms of Cisplatin Causes & Risk Factors for Cisplatin Diagnostic studies for Cisplatin Treatment of Cisplatin
Continuing Medical Education (CME)
CME Programs on Cisplatin
International
Cisplatin en Espanol Cisplatin en Francais
Business
Cisplatin in the Marketplace Patents on Cisplatin
Experimental / Informatics
List of terms related to Cisplatin

Overview

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Pharmacology

Upon administration, a chloride ligand undergo slow displacement with water (an aqua ligand) molecules, in a process termed aquation. The aqua ligand in the resulting [PtCl(H₂O)(NH₃)₂]⁺ is easily displaced, allowing cisplatin to coordinate a basic site in DNA. Subsequently, the platinum cross-links two bases via displacement of the other chloride ligand. Cisplatin crosslinks DNA in several different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair proves impossible.

Most notable among the DNA changes are the 1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand d(ApG) adducts. 1,3-intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision repair (NER) . Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to cisplatin's activity. Interaction with cellular proteins, particularly HMG domain proteins, has also been advanced as a mechanism of interfering with mitosis, although this is probably not its primary method of action.

trans-PtCl₂(NH₃)₂

The trans-[PtCl₂(H₂O)(NH₃)₂ does not exhibit a comparably useful pharmacological effect. Its low activity is generally thought to be due to rapid deactivation of the drug before it can arrive at the DNA. It is toxic, and it is desirable to test batches of cis-platin for the absence of the trans isomer. In a procedure by Woollins et al., which is based on the classic 'Kurnakov test', thiourea reacts with the sample to give derivatives are easily separated and detected by HPLC.

Side effects

Cisplatin has a number of side-effects that can limit its use:

• Nephrotoxicity (kidney damage) is a major concern when cisplatin is given. The dose is reduced when the patient's creatinine clearance (a measure of renal function) is reduced. Adequate hydration and diuresis is used to prevent renal damage. The nephrotoxicity of platinum-class drugs seems to be related to reactive oxygen species and in animal models can be ameliorated by free radical scavenging agents. This is a dose-limiting toxicity.
• Neurotoxicity (nerve damage) can be anticipated by performing nerve conduction studies before and after treatment.
• Nausea and vomiting. Cisplatin is one of the most emetogenic chemotherapy agents, but this is managed with prophylactic antiemetics (e.g. ondansetron, granisetron, etc.) in combination with corticosteroids. Aprepitant combined with ondansetron and dexamethasone has been shown to be better for highly emetogenic chemotherapy than just ondansetron and dexamethasone.
• Ototoxicity (hearing loss): unfortunately there is at present no effective treatment to prevent this side effect, which may be severe. Audiometric analysis may be necessary to assess the severity of ototoxicity. Other drugs (such as the aminoglycoside antibiotic class) may also cause ototoxicity, and the administration of this class of antibiotics in patients receiving cisplatin is generally avoided. The ototoxicity of both the aminoglycosides and cisplatin may be related to their ability to bind to melanin in the stria vascularis of the inner ear or the generation of reactive oxygen species.
• Alopecia (hair loss): this is generally not a major problem in patients treated with cisplatin.
• Electrolyte disturbance: Cisplatin can cause hypomagnesaemia, hypokalaemia and hypocalcaemia. The hypocalcaemia seems to occur in those with low serum magnesium secondary to cisplatin, so it is not primarily due to the Cisplatin.

History

The compound cis-PtCl₂(NH₃)₂ was first described by M. Peyrone in 1845 (known as Peyrone's salt). The structure was deduced by Alfred Werner in 1893. In the 1960s, Barnett Rosenberg and van Camp et al at Michigan State University discovered that electrolysis of a platinum electrode produced cisplatin, which inhibited binary fission in Escherichia coli (E. coli) bacteria. The bacteria grow to 300 times their normal length but cell division fails. Rosenberg then conducted a series of experiments to test the effects various platinum coordination complexes on sarcomas artificially implanted in rats. This study found that cis-diamminedichloroplatinum(II) was the most effective out of this group, which started the medicinal career of cisplatin.

Approved for clinical use by the United States Food and Drug Administration (FDA) in 1978, it revolutionized the treatment of certain cancers. Detailed studies on its molecular mechanism of action, using a variety of spectrocopic methods including X-ray, NMR spectroscopy, and other physico-chemical methods, revealed its ability to form irreversible crosslinks with bases in DNA.

Synthesis

Synthesis of cisplatin

The synthesis of cisplatin is a classic in inorganic chemistry. Starting from potassium tetrachloroplatinate, K₂PtCl₄²⁻, the first NH₃ ligand is added to any of the four equivalent positions, but the second NH₃ could be added cis or trans to the amine ligand. Because Cl⁻ has a larger trans effect than NH₃, the second amine substitutes trans to a chloride ligand, and therefore cis to the first amine. The trans effect of the halides follows the order I^->Br^->Cl^-, therefore the synthesis is conducted using PtI₄²⁻ to ensure high yield and purity of the cis isomer, followed by conversion of the PtI₂(NH₃)₂ into PtCl₂(NH₃)₂, as first described by Dhara.

External links

• Cisplatin: The Invention of an Anticancer Drug by Andri Smith
• [http://www2.mrc-lmb.cam.ac.uk/personal/sl/Html/Frames.html Cisplatin and its Analogues (excellent detailed overview)
• MedlinePlus page on cisplatin
• IARC Monograph: "Cisplatin"

Template:WikiDoc Sources